JP2017507943A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507943A5
JP2017507943A5 JP2016553897A JP2016553897A JP2017507943A5 JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5 JP 2016553897 A JP2016553897 A JP 2016553897A JP 2016553897 A JP2016553897 A JP 2016553897A JP 2017507943 A5 JP2017507943 A5 JP 2017507943A5
Authority
JP
Japan
Prior art keywords
composition
item
neu
osteosarcoma
listeria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507943A (ja
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed filed Critical
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/en
Publication of JP2017507943A publication Critical patent/JP2017507943A/ja
Publication of JP2017507943A5 publication Critical patent/JP2017507943A5/ja
Pending legal-status Critical Current

Links

JP2016553897A 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法 Pending JP2017507943A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/189,008 2014-02-25
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (2)

Publication Number Publication Date
JP2017507943A JP2017507943A (ja) 2017-03-23
JP2017507943A5 true JP2017507943A5 (enExample) 2018-08-02

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553897A Pending JP2017507943A (ja) 2014-02-25 2015-02-25 Ｈｅｒ２／ｎｅｕ過剰発現腫瘍の治療のための組成物および方法

Country Status (12)

Country Link
EP (1) EP3110942A4 (enExample)
JP (1) JP2017507943A (enExample)
KR (2) KR20240038103A (enExample)
CN (1) CN106661538A (enExample)
AU (1) AU2015223136A1 (enExample)
BR (1) BR112016019534A2 (enExample)
CA (1) CA2940646A1 (enExample)
IL (1) IL247436A0 (enExample)
MX (1) MX2016011114A (enExample)
RU (1) RU2016137834A (enExample)
SG (1) SG11201607036XA (enExample)
WO (1) WO2015130810A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
KR20140134695A (ko) 2012-03-12 2014-11-24 어드박시스, 인크. 리스테리아 백신 치료 후 억제 세포 기능 저해
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
MX2016011537A (es) * 2014-03-05 2017-05-01 Advaxis Inc Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
CA3035591A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Similar Documents

Publication Publication Date Title
JP2013526837A5 (enExample)
RU2016137834A (ru) КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu
US9969986B2 (en) Virus like particle comprising modified envelope protein E3
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
KR102713707B1 (ko) 신규 다가 나노입자 기반 백신
JP2017195888A5 (enExample)
ES2675825T3 (es) Vacunación tumoral que involucra una respuesta inmunitaria contra la proteína propia CLDN18.2
US10385101B2 (en) Virus like particle comprising modified envelope protein E3
CN118576699A (zh) Hbv疫苗
JP6039669B2 (ja) Ｈｅｒ２／ｎｅｕ発現腫瘍に対する薬剤の調製における弱毒化組換えリステリアの使用
JP2017513502A5 (enExample)
JP2018508212A5 (enExample)
JP2016156828A5 (enExample)
AU2017211387A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
JPWO2017175253A1 (ja) エキソソーム標的ｄｎａワクチン
CN115397462A (zh) 个体化治疗性抗癌疫苗
US11844824B2 (en) Nucleic acid molecules and methods of using the same
JP2024054375A (ja) エキソソーム標的ｄｎａワクチン
NZ723750B2 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
Bequet-Romero et al. Mutated variant of human vascular endothelial growth factor as a vaccine candidate for cancer immunotherapy